FXR has emerged as a potential therapeutic target for a variety of diseases, including primary biliary cholangitis (PBC)32,33, non-alcoholic fatty liver disease (NAFLD)34, and acute kidney injury.35 Therefore, we investigated the potential therapeutic effects of FXR pharmacological activation on osteoporosis. Here, NR1H4 is linked to primary biliary cholangitis.